Recombination of low and very low density lipoproteins (VLDL and LDL) from normal subjects with plasma from patients with non-insulin-dependent diabetes mellitus significantly increased the reduced rate of transfer of cholesteryl ester to these lipoproteins, which is characteristic of diabetic plasma, whereas diabetic VLDL and LDL reduced cholesteryl ester transfer rates in normal plasma. VLDL and LDL from diabetic plasma had an increased ratio of free cholesterol to phospholipid compared to normal, and unlike normal VLDL and LDL spontaneously lost free cholesterol to high density lipoprotein. These data suggest that the block to cholesteryl ester transfer to these lipoproteins in non-insulin-dependent diabetes is mediated by their increased free cholesterol content and may be related to the increased risk of these patients for developing atherosclerosis.
Although diabetes mellitus is defined by abnormal carbohydrate metabolism, it has been apparent for some time that disturbances of lipid metabolism are also commonly seen in this syndrome. This is particularly true of patients with noninsulin-dependent diabetes mellitus (NIDDM) . The plasma lipoprotein pattern of these individuals often shows increased levels of very low and low density lipoproteins (VLDL and LDL) and a decreased concentration of high density lipoprotein (HDL) (1) (2) (3) . Since these changes have been identified in epidemiological studies as factors associated with increased risk of coronary artery disease (4, 5) , they might be expected to play a role in the accelerated atherosclerosis associated with NIDDM (6) . In this regard, we have recently described (3) a consistent pattern of abnormal cholesterol metabolic activity in the plasma of patients with NIDDM, which may provide a link between defects in lipid metabolism and atherogenesis in this form of diabetes. Specifically, the transfer of cholesteryl esters synthesized by lecithin:cholesterol acyltransferase (LCATase) to VLDL and LDL is inhibited, and these esters are transferred instead to HDL. Two further observations increase the potential significance of this abnormal pathway. First, a similar defect has now been identified in the plasma of several other patient groups at high risk for coronary artery disease (7) . Second, the abnormal plasma cholesterol metabolism of the diabetic is normalized by the institution of good diabetic control with insulin (3) . In this paper we provide evidence that the block in cholesteryl ester transfer activity in patients with NIDDM is secondary to a change in the properties of VLDL and LDL, which is the result of an increase in the free cholesterol content of these lipoprotein particles.
MATERIALS AND METHODS
Subject Selection. Seven patients meeting the criteria for diagnosis of NIDDM (8) and eight normoglycemic controls were selected for this study. Mean glucose levels were 291 ± 16 and 93 ± 2 mg/dl in the two groups, mean cholesterol levels were 241 ± 19 and 158 ± 7 mg/dl, and mean triglyceride levels were 282 ± 61 and 75 ± 4 mg/dl (±SEM) (9) (10) (11) .
None of the diabetics had received any specific therapy for their hyperglycemia. Other characteristics of the diabetic and control groups were similar to those described (3). Blood was collected after an overnight fast into 0.05 vol of icecooled 0.2 M sodium citrate (pH 7.0). Plasma was obtained by centrifugation at 2000 x g for 30 min at 0-20C and used immediately for the assays described below.
Determination of the Rate of Cholesterol Esterification in Plasma. Plasma was brought to 0.01 M with TrisIHCl buffer (pH 7.4) and to 1 mM with Na2EDTA. Pentuplicate samples taken at zero time were extracted with chloroform/methanol (12) , and free cholesterol concentration was determined fluorimetrically (13) . Cholesterol esterification rate was calculated as the rate of decrease in plasma free cholesterol when plasma was incubated at 370C (3, 7) . This decrease was inhibited (>97%) by inclusion of 1.5 mM 5,5'-dithiobis(2-nitrobenzoic acid) (Nbs2), an inhibitor of LCATase (14) , in the incubation medium. This demonstrates that LCATase was the major or only source of de novo synthesis of cholesteryl esters in plasma under these conditions. Determination of Cholesteryl Ester Transfer. Plasma was brought to 0.01 M Tris HCl (pH 7.4) and 1 mM Na2EDTA and then mixed with 0.1 vol of 15 mM Nbs2 in 0.1 M phosphate buffer (pH 7.4) to inhibit LCATase (14) . An initial sample was mixed with 0.05 vol of 2 M MgCl2 and 0.05 vol of dextran sulfate (20 mg/ml; Pharmacia, Uppsala, Sweden) to precipitate total VLDL and LDL. After standing in ice for 30 min, the precipitate was removed by centrifugation (2000 x g, 30 min, at 0-20C) and pentuplicate samples of the supernatant solution were extracted and taken for analysis of free and esterified cholesterol (13) . The remainder of the plasma + Nbs2 was then incubated at 370C for 60 min and samples were taken as before for precipitation, centrifugation, and analysis. We have previously shown (15) VLDL and LDL. Any change in supernatant free cholesterol under the same conditions of incubation represents unlinked (LCATase-independent) net transfer of free cholesterol between HDL and VLDL + LDL.
Heparin-Agarose Column Chromatography. Chromatography was carried out at 40C by using columns (1 x 40 cm) of heparin-agarose (Pharmacia) equilibrated with 0.15 M NaCl/1 mM Na2EDTA, pH 7.4 (saline/EDTA). Plasma (3-4 ml) was passed through at 2-40C at a flow rate of 10-15 ml/hr, and fractions of nonadsorbed material containing detectable protein (16) or cholesterol (13) were pooled (2-3 plasma vol). After the column had been washed with a further 10 column vol of saline/EDTA, the adsorbed lipoproteins were eluted with 3 M NaCl/1 mM EDTA in =2 plasma vol and dialyzed against saline/EDTA. These lipoproteins were either reincorporated with the nonadsorbed fraction of plasma for studies of cholesterol metabolic activities or were fractionated by ultracentrifugation (35,000 rpm, 18 hr, 2-40C) at p 1.019 g/ml for analysis of lipoprotein lipid and protein composition. The lipoproteins were brought to the indicated density with KBr solution and centrifuged in a Beckman L3-40 or L3-50 preparative ultracentrifuge. In some studies the infranatant (LDL) fraction was recentrifuged at p 1.063 g/ml under the same conditions. The nonadsorbed fraction from heparin-agarose affinity chromatography was also centrifuged at p 1.019 g/ml, and floating lipoprotein was recovered for analysis.
Lipid and Lipoprotein Analysis. Immunoassays of lipoprotein proteins B and E were performed by the method of Mancini et al. (17) , as described (18, 19) .
Agarose strip gel electrophoresis of lipoproteins was carried out with 0.5% agarose in barbital buffer (pH 7.4) on polyester film (Gelbond, Bioproducts, Rockland, ME), essentially as described by Noble (20) . After development the strips were fixed in ethanol/acetic acid/water (75:5:20), air dried, stained in sudan black in 60% (vol/vol) ethanol/water, and then destained in ethanol/water.
The lipid composition of isolated plasma lipoproteins was determined after extraction into chloroform/methanol (12) . Portions of chloroform phase were taken for fluorimetric determination of free and esterified cholesterol (13) . Triglyceride and phospholipid were separated by thin-layer chromatography on layers of silicic acid on glass plates (Merck, Darmstadt, F.R.G.) and developed in hexane/diethyl ether/ acetic acid, 83:16:1 (vol/vol/vol). Triglyceride glycerol was determined after periodate oxidation with chromotropic acid (21) . Lipid phosphorus was determined with ammonium molybdate (22) . Lipoprotein cholesteryl esters, separated by thin-layer chromatography as described above, were hydrolyzed with methanol/sulfuric acid (23) . Fatty acid methyl esters were analyzed by gas/liquid chromatography (model 2920B with M-1 computerized integrator; Perkin-Elmer, Norwalk, CT), using a column of 5% DEGS-PS on 100/200 Supelcoport (Supelco, Bellefonte, PA).
RESULTS
When plasma from normoglycemic donors was incubated at 37°C, there was a mean increase in the amount of cholesteryl ester present in VLDL + LDL (15.6 + 4.8 ,ug/ml of plasma per hr). Since LCATase activity was inhibited by Nbs2, this represents the amount of cholesteryl ester transferred from HDL to VLDL and LDL. This transfer rate was significantly greater (P < 0.005) than the value of 3.1 ± 2.5 ug/ml of plasma per hr from patients with NIDDM. These results are similar to our previous observations (3), with subjects showing lower triglyceride levels, that cholesteryl ester transfer to VLDL + LDL in these diabetics is markedly reduced. Plasma from which VLDL and LDL had been removed by heparin-agarose affinity chromatography showed no detectable cholesteryl ester transfer in the precipitation assay (see Materials and Methods), indicating that only lipoproteins retained by heparin-agarose were of significance in cholesteryl ester transfer. In contrast to the finding with cholesteryl ester transfer, cholesteryl ester synthesis-i.e., the total increase in plasma cholesteryl ester-was similar in normal and diabetic subjects (28.6 ± 12.1 vs. 27.6 ± 7.3 ,tg of cholesterol esterified per ml of plasma per hr; P > 0.1), and in neither group was this rate reduced significantly by the removal of VLDL + LDL from the plasma. These findings indicated that the defect of cholesterol metabolism in diabetic plasma lay not in the generation of cholesteryl esters but in their transfer to HDL, rather than to VLDL and LDL.
One explanation of this defect in transfer would be that the acceptor lipoproteins (VLDL and LDL) present in diabetic plasma were themselves abnormal. To test this hypothesis, the nonadsorbed fraction of diabetic plasma from heparinagarose was recombined with the VLDL + LDL fraction from normoglycemic plasma, prepared by the same fractionation technique. As shown in Fig. 1 , the cholesteryl ester transfer rate, which was low in native diabetic plasma, was markedly stimulated (P < 0.02). Conversely, addition of VLDL + LDL from the plasma of NIDDM patients to the nonadsorbed fraction of control plasma markedly decreased (P < 0.05) the rate of cholesteryl ester transfer observed (Fig. 1) . These experimental results indicate that the abnormality in plasma from diabetic subjects that inhibits cholesteryl ester transfer lies in the VLDL and LDL retained by heparin-agarose.
Agarose gel electrophoresis indicated that the nonadsorbed fraction from heparin-agarose gel chromatography of plasma from either normal or diabetic subjects contained not only HDL but also a pre-f3-migrating fraction recovered in the supernatant fraction by centrifugation at a medium density of p 1.019 g/ml. The adsorbed lipoproteins contained the aB-migrating LDL and a second pre-p band recovered by flotation at p 1.019 g/ml. These electrophoretic patterns were unchanged following a second fractionation of the same material on heparin-agarose. Therefore, plasma from both normal subjects and patients with NIDDM contained two fractions of VLDL, separable by heparin-agarose chromatography. However, since cholesteryl ester transfer was not detectable in the nonadsorbed fraction of plasma from either normal or diabetic individuals, the nonadsorbed fraction of VLDL did not play a major role in transfer in the plasma.
The nonadsorbed and adsorbed fractions of VLDL and LDL were purified by flotation and their compositions were determined. As shown in Table 1 of VLDL from both normal and diabetic donors showed a higher concentration of triglyceride and a lower concentration of cholesteryl ester (both P < 0.001) than the adsorbed VLDL. The major cholesteryl ester fatty acid in both VLDL fractions and LDL from both diabetic and normal plasma was linoleate (C18g2) (data not shown), suggesting the origin of most of the cholesteryl ester in each lipoprotein from the LCATase reaction (24) . Also evident was a doubling of the triglyceride content of LDL isolated from diabetic plasma, a finding in agreement with earlier data (1). However, such a difference was not present when the VLDL of normal and diabetic plasma were compared. There was no difference between diabetic and normal plasma in the apoprotein composition of the equivalent lipoprotein fractions (data not shown). The nonadsorbed VLDL fraction of both diabetic and control plasma contained no detectable apolipoprotein E, while the apolipoprotein E/apolipoprotein B mass ratios of adsorbed VLDL, determined by specific immunoassay, were 0.55 ± 0.17 and 0.55 ± 0.14, respectively. The only observed consistent difference between each of the lipoproteins isolated from diabetic plasma and the corresponding lipoprotein from normal plasma lay in the consistently higher ratio (P < 0.005) of free cholesterol to phospholipid present in the lipoproteins from patients with NIDDM. If this difference were important in the inhibition of cholesteryl ester transfer in diabetic plasma, transfer would be expected to decrease as the free cholesterol/phospholipid weight ratio became greater. This relationship is observed in the data in Fig. 2 .
If the free cholesterol content of VLDL and LDL from diabetic patients were increased and if this increase were important in directing cholesteryl esters away from VLDL substantial rates of cholesteryl ester transfer to VLDL and LDL. Conversely, the chemical potential of cholesterol in diabetic VLDL and LDL was much greater than in diabetic HDL, as was shown by the much greater rate of spontaneous transfer of free cholesterol from these lipoproteins when LCATase was inhibited (6.0 ± 1.7 ug/ml of plasma per hr) (P < 0.005) and this was associated with a very low rate of cholesteryl ester transfer. These findings support the concept that increased acceptor free cholesterol content (rather than a decreased phospholipid content) is an important factor in the inhibition of cholesteryl ester transfer in diabetes.
Finally, if an increase in free cholesterol content of VLDL + LDL from diabetic subjects plays a role in the block of cholesteryl ester transfer, recombination experiments similar to those outlined in Fig. 1 , which modified cholesteryl ester transfer, should lead to predictable changes in free cholesterol transfer from VLDL + LDL to HDL. The results of such experiments, seen in Fig. 4 , support this concept. The rate of cholesteryl ester transfer from VLDL + LDL to HDL that occurs in plasma of normal subjects is seen in column A and confirms the fact that there is essentially no potential difference of free cholesterol between lipoproteins in the plasma of normal subjects. On the other hand, when VLDL + LDL from patients with diabetes are exchanged for -20r- HDL (dextran sulfate/MgCl2 supernatant fraction). However, the results in column C indicate that the free cholesterol transfer rate in plasma from diabetics is significantly reduced (P < 0.01) when the VLDL + LDL from normal patients are exchanged for native VLDL + LDL. These findings provide additional support for the concept that a free cholesterol gradient exists between VLDL + LDL and HDL in the plasma of patients with NIDDM and that the increased free cholesterol content of VLDL + LDL in NIDDM plays a major role in the inhibition of cholesteryl ester transfer to these lipoproteins.
DISCUSSION
The defect of cholesteryl ester transfer in diabetic plasma was largely reversed by the substitution of normal for diabetic VLDL + LDL in diabetic plasma. Conversely, the exchange of diabetic for normal VLDL + LDL in plasma from normal subjects led to a marked decrease in the cholesteryl ester transfer rate seen in the plasma of normal individuals. These data provide strong evidence that the inhibition of cholesteryl ester transfer seen in the plasma of patients with NIDDM is due to an abnormality in the acceptor lipoproteins, VLDL and LDL. The absence of detectable transfer to nonadsorbed VLDL may indicate a role for apolipoprotein E in transfer to VLDL; however, LDL, in the adsorbed fraction, appears in any case to be the major acceptor of cholesteryl ester in plasma (15) . Fractions with similar composition to nonadsorbed and adsorbed VLDL, separated by electrophoresis (25) or heparin-Sepharose chromatography (26) , have been identified; the former may represent nascent VLDL.
The evidence obtained suggests that it is the increased concentration of free cholesterol, found in both VLDL and LDL isolated from patients with NIDDM, that is responsible for the block of cholesteryl ester transfer. First, the level of free cholesterol relative to phospholipid was increased in both VLDL and LDL isolated from the plasma of patients with NIDDM as compared to normal subjects, and the block in cholesteryl ester transfer was inversely correlated with the increase in free cholesterol/phospholipid ratio of VLDL + LDL. In addition, net transfer of free cholesterol from VLDL + LDL to HDL could be documented in plasma of patients with NIDDM, indicative of the presence of a chemical potential gradient of free cholesterol between plasma lipoproteins in this situation. In contrast, essentially no transfer of free cholesterol from VLDL + LDL to HDL was seen in plasma from normals. Furthermore, the magnitude of the free cholesterol gradient between VLDL + LDL and HDL was inversely correlated with cholesteryl ester transfer rate. Finally, the degree of the free cholesterol gradient was increased in plasma from normal subjects when their VLDL + LDL were substituted with VLDL + LDL from diabetic subjects and decreased in plasma from patients with NIDDM when the corresponding substitution was made. Taken together, these data strongly support the concept that the free cholesterol content of VLDL + LDL is a determinant of cholesteryl ester transfer rate and that the increased free cholesterol/phospholipid ratio of these acceptor lipoproteins in NIDDM is a major factor in the reduced cholesteryl ester transfer rates that are a characteristic of this disease. The finding that cholesteryl ester transfer in diabetics was completely normalized by control VLDL + LDL (Fig. 1) under conditions in which the free cholesterol gradient was only partially reduced probably reflects an additional abnormality in the composition of the acceptor (HDL) fraction of diabetics, although this remains to be determined.
It is clear from the data in Table 1 (3, 7) and those contained in the present study, we suggest that it may be a common metabolic defect in the plasma of those at risk for atherosclerosis, including diabetics, that an increased acceptor lipoprotein free cholesterol content inhibits the normal pathway of cholesteryl ester transfer, by means of which in normal metabolism cholesterol of peripheral origin is returned to the liver for catabolism.
